TransMedics Group, Inc. $TMDX Shares Bought by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. increased its stake in TransMedics Group, Inc. by 135.8%, owning 145,393 shares valued at approximately $9.78 million as of the latest quarter.
• TransMedics Group reported $0.92 earnings per share for the last quarter, exceeding analysts' expectations by $0.44, alongside a revenue increase of 37.7% year-over-year.
• Institutional ownership stands at an impressive 99.67% of the company's stock, indicating strong support from institutional investors.

Raymond James Financial Inc. boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 135.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 145,393 shares of the company's stock after buying an additional 83,722 shares during the quarter. Raymond James Financial Inc. owned approximately 0.43% of TransMedics Group worth $9,782,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sit Investment Associates Inc. lifted its holdings in TransMedics Group by 8.8% during the first quarter. Sit Investment Associates Inc. now owns 7,380 shares of the company's stock valued at $497,000 after purchasing an additional 600 shares in the last quarter. Montanaro Asset Management Ltd lifted its holdings in TransMedics Group by 9.7% during the first quarter. Montanaro Asset Management Ltd now owns 153,675 shares of the company's stock valued at $10,339,000 after purchasing an additional 13,640 shares in the last quarter. HighTower Advisors LLC lifted its holdings in TransMedics Group by 137.7% during the first quarter. HighTower Advisors LLC now owns 18,257 shares of the company's stock valued at $1,228,000 after purchasing an additional 10,575 shares in the last quarter. Trillium Asset Management LLC lifted its holdings in TransMedics Group by 7.4% during the first quarter. Trillium Asset Management LLC now owns 35,389 shares of the company's stock valued at $2,381,000 after purchasing an additional 2,442 shares in the last quarter. Finally, Public Sector Pension Investment Board lifted its holdings in TransMedics Group by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 106,480 shares of the company's stock valued at $7,164,000 after purchasing an additional 22,894 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Performance

TMDX opened at $114.96 on Monday. The firm has a market capitalization of $3.92 billion, a PE ratio of 59.57 and a beta of 2.18. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $172.78. The firm's 50-day moving average price is $120.24 and its 200 day moving average price is $103.29. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. TransMedics Group's quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on TMDX. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday. Oppenheimer increased their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Finally, Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $123.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.